Trial Profile

An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amikacin (Primary)
Indications Mycobacterium avium complex infections; Nontuberculous mycobacterium infections
Focus Adverse reactions; Registrational
Sponsors Insmed

20 May 2020 Results of post hoc analyses evaluated the impact of baseline amikacin and clarithromycin minimum inhibitory concentration (MIC) on culture conversion rates, presented at the 116th International Conference of the American Thoracic Society.
15 Nov 2019 Status changed from recruiting to completed.
16 May 2019 This trial has been completed in Netherlands, according to European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com